N-terminal modified recombinant human endostatin and its production
AssigneeYantai Medgenn Ltd.
InventorsYongzhang Luo, Bing Zhou, Zhuobing Zhang
Life of this patent
Estimating the term…
Abstract
The invention relates to endostatin, protein, in particular, to N-terminal modified recombinant human endostatin (rhEndostatin) proteins which have an additional metal chelating peptide sequence at the N-terminal, the preparation thereof, and methods of modifying the rhEndostatin to improve its stability in vivo and in vitro, and its biological activity. The invention further related to the resulting N-terminal modified rhEndostatin protein, a pharmaceutical composition containing the same, and use of said modified rhEndostatin or its pharmaceutical composition in treating the angiogenesis-related diseases, especially angiogenesis-dependent tumors.
Claims30
A modified recombinant human endostatin, said modified endostatin comprising an additional metal chelating peptide sequence at its N-terminal.
A method of making a modified recombinant human endostatin, said method comprising providing a recombinant human endostatin having an additional metal chelating peptide at the N-terminal of said recombinant human endostatin.
Dependencies are inferred from the claim text.